CSF2 and Miyoshi myopathy: For example, a phase II randomized trial comparing ipilimumab (10 mg/kg) and systemic GM-CSF (sargramostim, 250 μg SC daily, d1-14) to ipilimumab alone in 245 MM patients, found that combination treatment conferred a greater OS (17.5 mo vs. 12.7 mo, HR = 0.64, p = 0.01) and a lower rate of grade 3–4 ADRs (44.9 vs. 58.3%, p = 0.04) [43].